10:52 AM
Mar 08, 2018
 |  BC Extra  |  Company News

Reed leaving Roche's pRED division

Roche (SIX:ROG; OTCQX:RHHBY) said John Reed, the head of its Pharma Research and Early Development unit, is leaving the company for "personal reasons" and returning to the U.S., effective April 2. William Pao, global head of the oncology discovery and translational area for pRED, will succeed Reed and will be based in Basel, Switzerland.

Prior to joining Roche in 2013, Reed was CEO at Sanford Burnham Prebys Medical Discovery Institute (La Jolla, Calif.). Pao, who joined the pharma in 2014, was previously a professor at Vanderbilt University and director of personalized cancer medicine at Vanderbilt-Ingram Cancer Center.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD